CXCR4 and osteosarcoma: Among CXCR4 inhibitors, AMD3100 is in clinical use for leukemia [15,16], and CTCE-9908 was granted approval by the FDA for osteosarcoma [17] based on its potent inhibitory activity in preclinical models of osteosarcoma [18].